Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.

Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record with a generic access-block page.SummaryDifference16%

- Check36 days agoChange DetectedThe revision label on the page has been updated from v3.6.5 to v3.6.6, signaling a new software release. This change does not modify the study details or user-facing content.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5 to reflect a routine update to the page's software version.SummaryDifference0.0%

- Check71 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, reflecting an update to the page's underlying system or template.SummaryDifference0.0%

- Check79 days agoChange DetectedThe page shows added and removed date markers (e.g., 2026-07-17, 2026-07-16, 2026-07) indicating update timestamps for the study record, suggesting administrative maintenance rather than content changes. This reflects maintenance activity rather than alterations to the trial information.SummaryDifference0.1%

- Check86 days agoChange DetectedNo additions or deletions were provided, so there are no identifiable changes to the page content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.